192 related articles for article (PubMed ID: 36567671)
1. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
Cullinane PW; de Pablo Fernandez E; König A; Outeiro TF; Jaunmuktane Z; Warner TT
Mov Disord; 2023 Feb; 38(2):162-177. PubMed ID: 36567671
[TBL] [Abstract][Full Text] [Related]
2. [Parkinson's disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches].
Troshneva AY; Ametov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):12-18. PubMed ID: 36412150
[TBL] [Abstract][Full Text] [Related]
3. The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Cheong JLY; de Pablo-Fernandez E; Foltynie T; Noyce AJ
J Parkinsons Dis; 2020; 10(3):775-789. PubMed ID: 32333549
[TBL] [Abstract][Full Text] [Related]
4. Onset and mortality of Parkinson's disease in relation to type II diabetes.
Pezzoli G; Cereda E; Amami P; Colosimo S; Barichella M; Sacilotto G; Zecchinelli A; Zini M; Ferri V; Bolliri C; Calandrella D; Bonelli MG; Cereda V; Reali E; Caronni S; Cassani E; Canesi M; Del Sorbo F; Soliveri P; Zecca L; Klersy C; Cilia R; Isaias IU
J Neurol; 2023 Mar; 270(3):1564-1572. PubMed ID: 36436068
[TBL] [Abstract][Full Text] [Related]
5. The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.
Ribarič S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673943
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's Disease, Diabetes and Cognitive Impairment.
Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and Parkinson's disease: A new target for disease modification?
Athauda D; Foltynie T
Prog Neurobiol; 2016; 145-146():98-120. PubMed ID: 27713036
[TBL] [Abstract][Full Text] [Related]
9. Therapies modulating insulin resistance in Parkinson's disease: A cross talk.
Sharma T; Kaur D; Grewal AK; Singh TG
Neurosci Lett; 2021 Apr; 749():135754. PubMed ID: 33610666
[TBL] [Abstract][Full Text] [Related]
10. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.
Labandeira CM; Fraga-Bau A; Arias Ron D; Muñoz A; Alonso-Losada G; Koukoulis A; Romero-Lopez J; Rodriguez-Perez AI
Front Neuroendocrinol; 2021 Jul; 62():100914. PubMed ID: 33845041
[TBL] [Abstract][Full Text] [Related]
11. Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.
Xxxx S; Ahmad MH; Rani L; Mondal AC
Mol Neurobiol; 2022 Jul; 59(7):4466-4487. PubMed ID: 35575870
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
13. Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a Mechanistic Approach.
Sabari SS; Balasubramani K; Iyer M; Sureshbabu HW; Venkatesan D; Gopalakrishnan AV; Narayanaswamy A; Senthil Kumar N; Vellingiri B
Mol Neurobiol; 2023 Aug; 60(8):4547-4573. PubMed ID: 37118323
[TBL] [Abstract][Full Text] [Related]
14. Insulin-releasing or insulin-sensitizing drugs in Parkinson's disease? Choosing a pathway.
Sánchez-Gómez A; Compta Y; Martí MJ
Parkinsonism Relat Disord; 2021 Dec; 93():109-110. PubMed ID: 34696974
[TBL] [Abstract][Full Text] [Related]
15. Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study.
Sánchez-Gómez A; Díaz Y; Duarte-Salles T; Compta Y; Martí MJ
Parkinsonism Relat Disord; 2021 Aug; 89():22-27. PubMed ID: 34216937
[TBL] [Abstract][Full Text] [Related]
16. Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
Victorino DB; Nejm M; Guimarães-Marques M; Scorza FA; Scorza CA
Pharmaceut Med; 2021 Jan; 35(1):11-19. PubMed ID: 33409802
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
Duarte AI; Candeias E; Correia SC; Santos RX; Carvalho C; Cardoso S; Plácido A; Santos MS; Oliveira CR; Moreira PI
Biochim Biophys Acta; 2013 Apr; 1832(4):527-41. PubMed ID: 23314196
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Aviles-Olmos I; Limousin P; Lees A; Foltynie T
Brain; 2013 Feb; 136(Pt 2):374-84. PubMed ID: 22344583
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
Ferrari F; Moretti A; Villa RF
Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
[TBL] [Abstract][Full Text] [Related]
20. Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches.
Bhattamisra SK; Shin LY; Saad HIBM; Rao V; Candasamy M; Pandey M; Choudhury H
CNS Neurol Disord Drug Targets; 2020; 19(3):174-183. PubMed ID: 32418534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
